We searched MEDLINE and PubMed for studies published between Jan 1, 2016, and July 31, 2019, with the search terms “HCV” or “hepatitis C virus”, and “epidemiology”, “key populations”, “natural history”, “extrahepatic manifestations”, “HIV-HCV co-infection”, “HBV-HCV co-infection”, “screening and diagnosis”, “point-of-care diagnostics”, “linkage to care”, “direct acting antivirals and hepatocellular carcinoma”, “ HCV positive donors”, “direct acting antivirals and organ transplantation” or
SeminarHepatitis C
Introduction
Persistent infection with hepatitis C virus (HCV) is a leading cause of chronic liver disease, resulting in 475 000 deaths in 2015.1 The estimated global HCV prevalence in 2015 was 1·0% (95% uncertainty interval [UI] 0·8–1·1), aggregating to 71·1 million viraemic individuals (95% UI 62·5–79·4) infected with HCV.1, 2
In 2016, WHO adopted a global hepatitis strategy to eliminate viral hepatitis as a public health threat by 2030, with ambitious targets: a 90% reduction in incident cases of hepatitis B and C and a 65% reduction in mortality.3 To reach these targets, 80% of treatment-eligible individuals with chronic hepatitis B virus (HBV) and HCV need access to care.
Unfortunately, only around 14 million (20%) people who were estimated to be infected with HCV in 2016 were diagnosed, 1·76 million (13%) people were treated, and 1·51 million (86%) of those treated were given direct-acting antivirals (DAAs).1 Between 2016 and 2017, the number of people infected with HCV who were treated increased from 1·76 million to 2·10 million, with the greatest increase occurring in middle-income countries. It is of concern that only 12 of 194 countries were on track to meet the 2030 WHO elimination targets in June, 2018. Screening, diagnosis, facilitated linkage to care, and sustainable access to affordable DAA regimens are all fundamental to achieve the WHO 2030 elimination targets.
Section snippets
Overview
Globally, 80% of all HCV infections occur in 31 countries, with six countries (China, Pakistan, Nigeria, Egypt, India, and Russia) accounting for greater than 50% of all infections.2 Prevalence data in many countries remains of low quality and requires constant reappraisal.2
An estimated 1·75 million new HCV infections (95% UI 1·57–2·12) occurred in 2015. Hepatitis C incidence is highest in the WHO European and Eastern Mediterranean regions. In 2015, an incidence of 61·8 cases per 100 000 people
Progression of liver disease with HCV infection
75–80% of individuals develop chronic infection after exposure to HCV; however, some surveys report a lower incidence. Cirrhosis and hepatic decompensation, which has an annualised risk of 2–5%, can develop as a result of chronic HCV infection. 15–20% of people with liver disease die during the first year following decompensation.45
Acute hepatitis C
Acute hepatitis C infection is typically anicteric, and less than 25% of cases are clinically apparent. Symptoms, if present, become apparent 2–26 weeks after HCV
Screening
Screening and linkage to treatment are fundamental prerequisites of the WHO elimination goals.55 Screening approaches vary by country, and although they are guided by HCV prevalence and dominant transmission routes, the approaches can be universal or targeted (eg, screening based on birth cohort or risk factors), or a combination of the two. WHO guidelines55, 56 recommend that serological testing for HCV be offered to individuals in a population with high HCV prevalence or to those who have a
Effectiveness of therapy
The primary goal of therapy is to achieve undectable HCV RNA—or an SVR—12 weeks (SVR12) or 24 weeks (SVR24) after the end of therapy, and is judged on the basis of a sensitive molecular assay with an acceptable lower limit of quantification.67 Concordance between SVR12 and SVR24 surpasses 99%.67 If a less sensitive HCV RNA test method or HCVcAg is used, SVR24 should be confirmed.51, 63 SVR is associated with improved liver-related and all-cause morbidity and mortality, and it is also associated
HCV–HIV co-infection
HCV–HIV co-infection increases the likelihood of progression to advanced liver fibrosis and cirrhosis and increases the risk of hepatocellular carcinoma. However, more than 95% of patients who are monoinfected with HCV or co-infected with HCV attain SVR following 8–12 weeks of DAA therapy.122 Potential complex drug–drug interactions between DAAs and antiretroviral therapy should be assessed before therapy is given.
HCV–HBV co-infection
HCV is often the dominant driver of chronic inflammatory activity in patients who
DAA therapy and risk of hepatocellular carcinoma
The effect of achieving SVR following DAA therapy on the risk of hepatocellular carcinoma occurrence and recurrence has been controversial.142 A systematic review and meta-analysis143 compared the risk of the occurrence and recurrence of hepatocellular carcinoma in 41 studies (n=13 875 patients); of these, 26 studies analysed de-novo occurrence of hepatocellular carcinoma (17 studies with interferon and nine studies that used DAAs), and 17 analysed the recurrence of hepatocellular carcinoma
Conclusion
HCV is a global health problem, but elimination is now possible with curative DAA therapy. Achievement of elimination will require increased diagnosis and linkage to care and universal access to affordable diagnostics and pangenotypic DAA therapy. Identifying and decriminalising key HCV-infected populations, such as PWID and MSM, and combining treatment with expansion of PWID harm reduction services, to break cycles of infection and reinfection, are essential. Upscaling blood safety programmes
Search strategy and selection criteria
References (165)
- et al.
Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis
Lancet Infect Dis
(2016) - et al.
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
Lancet Gastroenterol Hepatol
(2019) - et al.
Hepatitis C: global epidemiology and strategies for control
Clin Microbiol Infect
(2016) - et al.
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
Lancet Glob Health
(2017) - et al.
Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study
Lancet Infect Dis
(2015) - et al.
Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030
Lancet Gastroenterol Hepatol
(2017) - et al.
Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model
Lancet
(2019) - et al.
Hepatitis C treatment as prevention: evidence, feasibility, and challenges
Lancet Gastroenterol Hepatol
(2016) - et al.
Long-term effect of the Portuguese universal access program to new generation direct-acting antivirals for the treatment of hepatitis C
J Hepatol
(2016) - et al.
Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study
Lancet Infect Dis
(2018)
Hepatitis C transmission and treatment as prevention—the role of the injecting network
Int J Drug Policy
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
J Hepatol
Natural history of hepatitis C
Gastroenterology Clinics of North America
A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection
J Hepatol
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study
Lancet Infect Dis
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial
Lancet Gastroenterol Hepatol
Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial
J Hepatol
Extrahepatic morbidity and mortality of chronic hepatitis C
Gastroenterology
Characteristics of patients with hepatitis B virus and hepatitis C virus dual infection in a western European country: comparison with monoinfected patients
Clin Res Hepatol Gastroenterol
Universal screening for hepatitis C: an important step in virus elimination
Clin Gastroenterol Hepatol
Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: analysis of a global dataset
J Hepatol
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
Lancet
American Gastroenterological Association Institute guideline on the role of elastography in the evaluation of liver fibrosis
Gastroenterology
Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C
J Hepatol
Hepatitis C Virus Resistance to direct-acting antiviral drugs in interferon-free regimens
Gastroenterology
Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
J Virus Erad
SAT-244—Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network
J Hepatol
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
Lancet Infect Dis
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study
Lancet Infect Dis
Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial
Lancet Gastroenterol Hepatol
Global hepatitis report 2017
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Lancet Gastroenterol Hepatol
Global health sector strategy on viral hepatitis 2016–2021
Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes
J Infect Dis
Global distribution and prevalence of hepatitis C virus genotypes
Hepatology
Pangenotypic treatment regimens for hepatitis C virus: advantages and disadvantages in high- and low-income regions
J Viral Hepat
Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions
Sci Rep
Clinical profile of hepatitis C virus infection in a developing country: India
J Gastroenterol Hepatol
The epidemiology of hepatitis C virus in Central Asia: systematic review, meta-analyses, and meta-regression analyses
Sci Rep
Evolution of the global burden of viral infections from unsafe medical injections, 2000–2010
PLoS One
Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination
Int J Epidemiol
The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia
Virol J
Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis
Int J STD AIDS
Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review
Sex Health
Sexual behaviour, recreational drug use and hepatitis C co-infection in HIV-diagnosed men who have sex with men in the United Kingdom: results from the ASTRA study
J Int AIDS Soc
MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection
AIDS
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study
Hepatology
Vertical transmission of hepatitis C virus: systematic review and meta-analysis
Clin Infect Dis
Prevalence of drug injection, sexual activity, tattooing, and piercing among prison inmates
Epidemiol Rev
Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis
Addiction
Cited by (284)
Hepatitis C virus-positive donors in HCV-negative recipients in liver transplantation: Is it possible in Mexico?
2023, Revista de Gastroenterologia de MexicoPredictive plasma biomarkers of long-term increase in hepatic steatosis index after HCV eradication in HIV/HCV-coinfected patients
2023, Biomedicine and PharmacotherapyThe Global Burden of Liver Disease
2023, Clinical Gastroenterology and HepatologyBiosensor-based multiple cross displacement amplification platform for visual and rapid identification of hepatitis C virus
2024, Journal of Medical Virology